Skip to main content
Erschienen in: Pediatric Nephrology 3/2014

01.03.2014 | Review

The bioartificial kidney: current status and future promise

verfasst von: H. David Humes, Deborah Buffington, Angela J. Westover, Shuvo Roy, William H. Fissell

Erschienen in: Pediatric Nephrology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

The rapid understanding of the cellular and molecular bases of organ function and disease processes will be translated in the next decade into new therapeutic approaches to a wide range of clinical disorders, including acute and chronic renal failure. Central to these new therapies are the developing technologies of cell therapy and tissue engineering, which are based on the ability to expand stem or progenitor cells in tissue culture to perform differentiated tasks and to introduce these cells into the patient either via extracorporeal circuits or as implantable constructs. Cell therapy devices are currently being developed to replace the filtrative, metabolic, and endocrinologic functions of the kidney lost in both acute and chronic renal failure. This review summarizes the current state of development of a wearable or implantable bioartificial kidney. These devices have the promise to be combined to produce a wearable or implantable bioartificial kidney for full renal replacement therapy that may significantly diminish morbidity and mortality in patients with acute or chronic kidney disease.
Literatur
2.
Zurück zum Zitat Fissell WH, Fleischman AJ, Humes HD, Roy S (2007) Development of continuous implantable renal replacement: past and future. Transl Res 150(6):327–336PubMedCrossRef Fissell WH, Fleischman AJ, Humes HD, Roy S (2007) Development of continuous implantable renal replacement: past and future. Transl Res 150(6):327–336PubMedCrossRef
3.
Zurück zum Zitat Johnston K, Humes HD (2011) Extracorporeal renal replacement. In: Principles of regenerative medicine, second edition. Elsevier, Ann Arbor, MI, pp. 943–953 Johnston K, Humes HD (2011) Extracorporeal renal replacement. In: Principles of regenerative medicine, second edition. Elsevier, Ann Arbor, MI, pp. 943–953
4.
Zurück zum Zitat Roy S, Goldman K, Marchant R, Zydney A, Brown D, Fleischman A, Conlisk A, Desai T, Duffy S, Humes H, Fissell W (2011) Implanted renal replacement for end-stage renal disease. Panminerva Med 53(3):155–166PubMed Roy S, Goldman K, Marchant R, Zydney A, Brown D, Fleischman A, Conlisk A, Desai T, Duffy S, Humes H, Fissell W (2011) Implanted renal replacement for end-stage renal disease. Panminerva Med 53(3):155–166PubMed
5.
Zurück zum Zitat MacKay SM, Funke AJ, Buffington DA, Humes HD (1998) Tissue engineering of a bioartificial renal tubule. ASAIO J 44:179–183PubMedCrossRef MacKay SM, Funke AJ, Buffington DA, Humes HD (1998) Tissue engineering of a bioartificial renal tubule. ASAIO J 44:179–183PubMedCrossRef
6.
Zurück zum Zitat Nikolovski J, Gulari E, Humes HD (1999) Design engineering of a bioartificial renal tubule cell therapy device. Cell Transplant 8(4):351–364PubMed Nikolovski J, Gulari E, Humes HD (1999) Design engineering of a bioartificial renal tubule cell therapy device. Cell Transplant 8(4):351–364PubMed
7.
Zurück zum Zitat Humes HD, Cieslinski DA (1992) Interaction between growth factors and retinoic acid in the induction of kidney tubulogenesis in tissue culture. Exp Cell Res 201:8–15PubMedCrossRef Humes HD, Cieslinski DA (1992) Interaction between growth factors and retinoic acid in the induction of kidney tubulogenesis in tissue culture. Exp Cell Res 201:8–15PubMedCrossRef
8.
Zurück zum Zitat Humes HD, Krauss JC, Cieslinski DA, Funke AJ (1996) Tubulogenesis from isolated single cells of adult mammalian kidney: clonal analysis with a recombinant retrovirus. Am J Physiol 271(40):F42–F49PubMed Humes HD, Krauss JC, Cieslinski DA, Funke AJ (1996) Tubulogenesis from isolated single cells of adult mammalian kidney: clonal analysis with a recombinant retrovirus. Am J Physiol 271(40):F42–F49PubMed
9.
Zurück zum Zitat O’Neil JJ, Stegemann JP, Nicholson DT, Mullon CJ-P, Maki T, Monaco AP, Solomon BA (1997) Immunoprotection provided by the bioartificial pancreas in a xenogeneic host. Transplant Proc 29:2116–2117PubMedCrossRef O’Neil JJ, Stegemann JP, Nicholson DT, Mullon CJ-P, Maki T, Monaco AP, Solomon BA (1997) Immunoprotection provided by the bioartificial pancreas in a xenogeneic host. Transplant Proc 29:2116–2117PubMedCrossRef
10.
Zurück zum Zitat Humes HD, MacKay SM, Funke AJ, Buffington DA (1999) Tissue engineering of a bioartificial renal tubule assist device: in vitro transport and metabolic characteristics. Kidney Int 55:2502–2514PubMedCrossRef Humes HD, MacKay SM, Funke AJ, Buffington DA (1999) Tissue engineering of a bioartificial renal tubule assist device: in vitro transport and metabolic characteristics. Kidney Int 55:2502–2514PubMedCrossRef
11.
Zurück zum Zitat Humes HD, Buffington DA, MacKay SM, Funke AJ, Weitzel WF (1999) Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat Biotechnol 17:451–455PubMedCrossRef Humes HD, Buffington DA, MacKay SM, Funke AJ, Weitzel WF (1999) Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat Biotechnol 17:451–455PubMedCrossRef
12.
Zurück zum Zitat Breen D, Bihari D (1998) Acute renal failure as a part of multiple organ failure: the slippery slope of critical illness. Kidney Int 66(Suppl):S25–S33 Breen D, Bihari D (1998) Acute renal failure as a part of multiple organ failure: the slippery slope of critical illness. Kidney Int 66(Suppl):S25–S33
13.
Zurück zum Zitat Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock: relation to multiple-system organ failure and mortality. Chest 103:565–575PubMedCrossRef Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock: relation to multiple-system organ failure and mortality. Chest 103:565–575PubMedCrossRef
14.
Zurück zum Zitat Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS (1998) Hypovitaminosis D in medical inpatients. N Engl J Med 338:777–783PubMedCrossRef Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS (1998) Hypovitaminosis D in medical inpatients. N Engl J Med 338:777–783PubMedCrossRef
15.
Zurück zum Zitat Fissell WH, Dyke DB, Weitzel WF, Buffington DA, Westover AJ, MacKay SM, Gutierrez JM, Humes HD (2002) Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals. Blood Purif 20:55–60PubMedCrossRef Fissell WH, Dyke DB, Weitzel WF, Buffington DA, Westover AJ, MacKay SM, Gutierrez JM, Humes HD (2002) Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals. Blood Purif 20:55–60PubMedCrossRef
16.
Zurück zum Zitat Fissell WH, Lou L, Abrishami S, Buffington DA, Humes HD (2003) Bioartificial kidney ameliorates Gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol 14:454–461PubMedCrossRef Fissell WH, Lou L, Abrishami S, Buffington DA, Humes HD (2003) Bioartificial kidney ameliorates Gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol 14:454–461PubMedCrossRef
17.
Zurück zum Zitat Humes HD, Buffington DA, Lou L, Abrishami S, Wang M, Xia J, Fissell WH (2003) Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock. Crit Care Med 31:2421–2428PubMedCrossRef Humes HD, Buffington DA, Lou L, Abrishami S, Wang M, Xia J, Fissell WH (2003) Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock. Crit Care Med 31:2421–2428PubMedCrossRef
18.
Zurück zum Zitat Humes HD, Weitzel WF, Bartlett RH, Swaniker FC, Paganini EP, Luderer JR, Sobota J (2004) Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 66:1578–1588PubMedCrossRef Humes HD, Weitzel WF, Bartlett RH, Swaniker FC, Paganini EP, Luderer JR, Sobota J (2004) Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 66:1578–1588PubMedCrossRef
19.
Zurück zum Zitat Tumlin J, Wali R, Brennan K, Humes HD (2008) Efficacy and safety of renal tubule therapy for acute renal failure. J Am Soc Nephrol 19:1034–1040PubMedCrossRef Tumlin J, Wali R, Brennan K, Humes HD (2008) Efficacy and safety of renal tubule therapy for acute renal failure. J Am Soc Nephrol 19:1034–1040PubMedCrossRef
20.
Zurück zum Zitat Humes HD, Sobota JT, Ding F, Song JH, The RAD Investigator Group (2010) A selective cytopheretic inhibitory device (SCD) to treat the immunologic dysregulation of acute and chronic renal failure. Blood Purif 29:183–190PubMedCrossRef Humes HD, Sobota JT, Ding F, Song JH, The RAD Investigator Group (2010) A selective cytopheretic inhibitory device (SCD) to treat the immunologic dysregulation of acute and chronic renal failure. Blood Purif 29:183–190PubMedCrossRef
21.
Zurück zum Zitat Ding F, Yevzlin AS, Humes HD (2010) A selective cytopheretic inhibitory device (SCD) accelerates renal recovery and improves mortality in ICU patients with AKI and MOF in an exploratory clinical study. ASAIO J 56:140CrossRef Ding F, Yevzlin AS, Humes HD (2010) A selective cytopheretic inhibitory device (SCD) accelerates renal recovery and improves mortality in ICU patients with AKI and MOF in an exploratory clinical study. ASAIO J 56:140CrossRef
22.
Zurück zum Zitat Tumlin JA, Chawla L, Tolwani AJ, Mehta R, Dillon J, Finkel KW, Dasilva JR, Astor BC, Yevzlin AS, Humes HD (2012) The effect of the selective cytopheretic device on acute kidney injury outcomes in the intensive care unit: a multicenter pilot study. Semin Dial. doi:10.1111/sdi.12032 PubMed Tumlin JA, Chawla L, Tolwani AJ, Mehta R, Dillon J, Finkel KW, Dasilva JR, Astor BC, Yevzlin AS, Humes HD (2012) The effect of the selective cytopheretic device on acute kidney injury outcomes in the intensive care unit: a multicenter pilot study. Semin Dial. doi:10.​1111/​sdi.​12032 PubMed
23.
Zurück zum Zitat Pino CJ, Yevzlin AS, Lee K, Westover AJ, Smith PL, Buffington DA, Humes HD (2013) Cell-based approaches for the treatment of systemic inflammation. Nephrol Dial Transplant 28(2):296–302PubMedCrossRef Pino CJ, Yevzlin AS, Lee K, Westover AJ, Smith PL, Buffington DA, Humes HD (2013) Cell-based approaches for the treatment of systemic inflammation. Nephrol Dial Transplant 28(2):296–302PubMedCrossRef
24.
Zurück zum Zitat Orive G, Hernández RM, Gascon AR, Calafiore R, Chang TM, DeVos P, Hortelano G, Hunkeler D, Lacík I, Shapiro AM, Pedraz JL (2003) Cell encapsulation: promise and progress. Nat Med 9:104–107PubMedCrossRef Orive G, Hernández RM, Gascon AR, Calafiore R, Chang TM, DeVos P, Hortelano G, Hunkeler D, Lacík I, Shapiro AM, Pedraz JL (2003) Cell encapsulation: promise and progress. Nat Med 9:104–107PubMedCrossRef
25.
Zurück zum Zitat Richardson TP, Peters MC, Ennett AB, Mooney DJ (2001) Polymeric system for dual growth factor delivery. Nat Biotechnol 19:1029–1034PubMedCrossRef Richardson TP, Peters MC, Ennett AB, Mooney DJ (2001) Polymeric system for dual growth factor delivery. Nat Biotechnol 19:1029–1034PubMedCrossRef
26.
Zurück zum Zitat Westover AJ (2012) Enhanced propagation of adult human renal epithelial progenitor cells to improve cell sourcing for tissue-engineered therapeutic devices for renal disease. J Tissue Eng Regen Med 6(8):589–597PubMedCentralPubMedCrossRef Westover AJ (2012) Enhanced propagation of adult human renal epithelial progenitor cells to improve cell sourcing for tissue-engineered therapeutic devices for renal disease. J Tissue Eng Regen Med 6(8):589–597PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Buffington DA, Pino CJ, Hageman GM, Chen L, Humes HD (2012) Bioartificial renal epithelial cell systems (BRECS): a compact, cryopreservable extracorporeal renal replacement device. Cell Transplant. doi:10.3727/215517911X653328 Buffington DA, Pino CJ, Hageman GM, Chen L, Humes HD (2012) Bioartificial renal epithelial cell systems (BRECS): a compact, cryopreservable extracorporeal renal replacement device. Cell Transplant. doi:10.​3727/​215517911X653328​
28.
Zurück zum Zitat Pino CJ, Humes HD (2011) Bioartificial kidney: comprehensive biomaterials, vol 6. Elsevier, Oxford Pino CJ, Humes HD (2011) Bioartificial kidney: comprehensive biomaterials, vol 6. Elsevier, Oxford
29.
Zurück zum Zitat Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347:2010–2019PubMedCrossRef Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347:2010–2019PubMedCrossRef
30.
Zurück zum Zitat Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL (1998) Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32:107–114PubMedCrossRef Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL (1998) Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32:107–114PubMedCrossRef
31.
Zurück zum Zitat Gura V, Beizai M, Ezon C, Polaschegg HD (2005) Continuous renal replacement therapy for end-stage renal disease. The wearable artificial kidney (WAK). Contrib Nephrol 149:325PubMedCrossRef Gura V, Beizai M, Ezon C, Polaschegg HD (2005) Continuous renal replacement therapy for end-stage renal disease. The wearable artificial kidney (WAK). Contrib Nephrol 149:325PubMedCrossRef
32.
Zurück zum Zitat Roberts M, Ash SR, Lee DB (1999) Innovative peritoneal dialysis: flow-thru and dialysate regeneration. ASAIO J 45(5):372–378PubMedCrossRef Roberts M, Ash SR, Lee DB (1999) Innovative peritoneal dialysis: flow-thru and dialysate regeneration. ASAIO J 45(5):372–378PubMedCrossRef
33.
Zurück zum Zitat Westover A, Buffington D, Jung J, Lou L, Rojas A, Charles L, Smith P, Johnston K, Pino C, Humes D (2010) Uremic ovine model of end-stage renal disease (ESRD) for the evaluation of the bioartificial renal epithelial cell system (BRECS) 3(abstract). J Am Soc Nephrol 21:201 Westover A, Buffington D, Jung J, Lou L, Rojas A, Charles L, Smith P, Johnston K, Pino C, Humes D (2010) Uremic ovine model of end-stage renal disease (ESRD) for the evaluation of the bioartificial renal epithelial cell system (BRECS) 3(abstract). J Am Soc Nephrol 21:201
34.
Zurück zum Zitat Ash SR, Janie EM (1997) Continuous flow-through peritoneal dialysis (CFPD) comparison of efficiency to IPD, TPD, and CAPD in an animal model. Perit Dial Int 17:365–372PubMed Ash SR, Janie EM (1997) Continuous flow-through peritoneal dialysis (CFPD) comparison of efficiency to IPD, TPD, and CAPD in an animal model. Perit Dial Int 17:365–372PubMed
35.
Zurück zum Zitat Ronco C, Davenport A, Gura V (2008) A wearable artificial kidney: dream or reality? Nat Clin Pract Nephrol 4:604–605PubMedCrossRef Ronco C, Davenport A, Gura V (2008) A wearable artificial kidney: dream or reality? Nat Clin Pract Nephrol 4:604–605PubMedCrossRef
36.
Zurück zum Zitat Kanani DM, Fissell WH, Roy S, Dubnisheva A, Fleischman A, Zydney AL (2010) Permeability-selectivity analysis for ultrafiltration: effect of pore geometry. J Membr Sci 349:405–410CrossRef Kanani DM, Fissell WH, Roy S, Dubnisheva A, Fleischman A, Zydney AL (2010) Permeability-selectivity analysis for ultrafiltration: effect of pore geometry. J Membr Sci 349:405–410CrossRef
37.
Zurück zum Zitat Fissell WH, Dubnisheva A, Eldridge AN, Fleischman AJ, Zydney AL, Roy S (2009) High-performance silicon nanopore hemofiltration membranes. J Membr Sci 326:58–63CrossRef Fissell WH, Dubnisheva A, Eldridge AN, Fleischman AJ, Zydney AL, Roy S (2009) High-performance silicon nanopore hemofiltration membranes. J Membr Sci 326:58–63CrossRef
38.
Zurück zum Zitat Groszek J, Li L, Ferrell N, Smith R, Zorman CA, Hofmann CL, Roy S, Fissell WH (2010) Molecular conformation and filtration properties of anionic Ficoll. Am J Physiol Renal Physiol 299:F752–F757PubMedCrossRef Groszek J, Li L, Ferrell N, Smith R, Zorman CA, Hofmann CL, Roy S, Fissell WH (2010) Molecular conformation and filtration properties of anionic Ficoll. Am J Physiol Renal Physiol 299:F752–F757PubMedCrossRef
39.
Zurück zum Zitat Muthusubramaniam L, Lowe R, Fissell WH, Li L, Marchant RE, Desai TA, Roy S (2011) Hemocompatibility of silicon-based substrates for biomedical implant applications. Ann Biomed Eng 39(4):1296–1305PubMedCentralPubMedCrossRef Muthusubramaniam L, Lowe R, Fissell WH, Li L, Marchant RE, Desai TA, Roy S (2011) Hemocompatibility of silicon-based substrates for biomedical implant applications. Ann Biomed Eng 39(4):1296–1305PubMedCentralPubMedCrossRef
Metadaten
Titel
The bioartificial kidney: current status and future promise
verfasst von
H. David Humes
Deborah Buffington
Angela J. Westover
Shuvo Roy
William H. Fissell
Publikationsdatum
01.03.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 3/2014
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-013-2467-y

Weitere Artikel der Ausgabe 3/2014

Pediatric Nephrology 3/2014 Zur Ausgabe

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.